!autogenerated-by:     DAG-Edit version 1.311
!saved-by:             mgruenb
!date:                 Fri Jul 26 16:35:12 BST 2002
!version: $Revision: 1.1 $
! The Pathbase mouse pathology ontology provides a description of mutant and transgenic
! mouse pathology phenotypes and incorporates 425 known mouse pathologies hierarchically
! organised as "instances of" pathological processes.
!
! Questions, comments and suggestions for amendment should be sent to the
!   Co-ordinator, Dr. Paul Schofield, Dept. of Anatomy, University of Cambridge
!   (PS@mole.bio.cam.ac.uk).
!
! The ontology was developed by the Pathbase consortium (http://www.pathbase.net)
!  funded under the European Commission's Fifth Framework programme, 
!  Contract number QLRI-CT-1999-00320.
!
$pathology_ontology ; MPATH:0
 %cell and tissue damage ; MPATH:1
  %cell death ; MPATH:2
   %apoptosis ; MPATH:3
   %necrosis ; MPATH:4
    %bridging necrosis ; MPATH:5
    %caseous necrosis ; MPATH:6
    %coagulation necrosis ; MPATH:7
    %fat necrosis ; MPATH:8
    %fibrinoid necrosis ; MPATH:9
    %gangrene ; MPATH:10
    %hemorrhagic necrosis ; MPATH:11
    %liquefactive necrosis ; MPATH:12
    %piecemeal necrosis ; MPATH:13
  %degenerative change ; MPATH:14
   %general degenerative change ; MPATH:15
    %myxoid/myxomatous degeneration ; MPATH:16
   %subcellular defect ; MPATH:17
    %cytoskeletal defect ; MPATH:18
    %endoplasmic reticulum defect ; MPATH:19
    %golgi defect ; MPATH:20
    %lysosomal defect ; MPATH:21
    %mitochondrial defect ; MPATH:22
    %peroxisomal defect ; MPATH:23
    %plasma membrane defect ; MPATH:24
   %tissue specific degenerative process ; MPATH:25
    %alopecia ; MPATH:26
    %arthrosis ; MPATH:27
    %atherosclerosis ; MPATH:28
    %cataract ; MPATH:29
    %cystic media necrosis ; MPATH:30
    %emphysema ; MPATH:31
    %glaucoma ; MPATH:32
  %intracellular and extracellular accumulation ; MPATH:33
   %amyloid deposition ; MPATH:34
   %bile deposition ; MPATH:35
   %calcium deposition ; MPATH:36
   %ceroid deposition ; MPATH:37
   %copper deposition ; MPATH:38
   %glycogen deposition ; MPATH:39
   %hyalinosis ; MPATH:40
   %iron deposition ; MPATH:41
   %lipid deposition ; MPATH:42
   %lipofuscin deposition ; MPATH:43
   %melanin deposition ; MPATH:44
   %protein deposition ; MPATH:45
   %uric acid deposition ; MPATH:46
  %intracellular and extracellular depletion ; MPATH:47
   %decalcification ; MPATH:48
   %demyelination ; MPATH:49
   %glycogen depletion ; MPATH:50
   %hypocalcification ; MPATH:51
   %lipid depletion ; MPATH:52
   %osteopenia ; MPATH:53
   %osteoporosis ; MPATH:54
 %developmental and structural abnormality ; MPATH:55
  %general developmental defect ; MPATH:56
   %agenesis ; MPATH:57
   %aplasia ; MPATH:58
   %branching morphogenesis defect ; MPATH:59
   %communication defect ; MPATH:60
   %curvature defect ; MPATH:61
   %cyst ; MPATH:62
   %depletion ; MPATH:63
   %developmental dysplasia ; MPATH:64
   %developmental hypoplasia ; MPATH:65
   %dilatation ; MPATH:66
   %displacement and deformity ; MPATH:67
   %diverticulum ; MPATH:68
   %ectopia ; MPATH:69
   %fistula ; MPATH:70
   %fusion defect; MPATH:71
   %growth acceleration ; MPATH:72
   %growth arrest ; MPATH:73
   %hamartoma/choristoma ; MPATH:74
   %hernia ; MPATH:75
   %heterotopia ; MPATH:76
   %homoeotic change ; MPATH:77
   %incomplete closure ; MPATH:78
   %malposition ; MPATH:79
   %obstruction and stenosis ; MPATH:80
   %perforation ; MPATH:81
   %persistent embryonic structure ; MPATH:82
   %septation defect; MPATH:83
   %supernumerary structure ; MPATH:84
   %transdifferentiation ; MPATH:85
  %organ specific developmental defect ; MPATH:86
   %germ cell defect ; MPATH:87
   %nephroblastomatosis ; MPATH:88
   %cardiovascular developmental defect ; MPATH:89
    %aneurysm ; MPATH:90
    %arteriovenous anastomosis ; MPATH:91
    %cardiac defect ; MPATH:92
     %cardiac septation defect ; MPATH:93
     %valve defect ; MPATH:94
     %ventricular hyperplasia ; MPATH:95
     %ventricular hypoplasia ; MPATH:96
    %dissecting aneurysm ; MPATH:97
    %lymphangiectasis ; MPATH:98
    %varices ; MPATH:99
   %placental abnormality ; MPATH:100
    %glycogen cell defect ; MPATH:101
    %labyrinth zone defect ; MPATH:102
    %placental vascular defect ; MPATH:103
    %spongiotrophoblast defect ; MPATH:104
 %circulation disorder ; MPATH:105
  %fluid accumulation ; MPATH:106
  %congestion ; MPATH:107
  %disseminated intravascular coagulation ; synonym:dic ; MPATH:108
  %edema ; MPATH:109
  %embolus ; MPATH:110
   %air embolism ; MPATH:111
   %amniotic fluid embolism ; MPATH:112
   %atrial embolism ; MPATH:113
   %bone marrow embolism ; MPATH:114
   %fat embolism ; MPATH:115
   %pulmonary embolism ; MPATH:116
   %skin embolism ; MPATH:117
   %systemic embolism ; MPATH:118
  %hemorrhage and non-specified extravasation ; MPATH:119
   %ecchymosis ; MPATH:120
   %hematoma ; MPATH:121
   %petechia ; MPATH:122
   %purpura ; MPATH:123
  %infarction ; MPATH:124
  %thrombosis ; MPATH:125
 %growth and differentiation defect ; MPATH:126
  %atrophy ; MPATH:127
  %dysplasia ; MPATH:128
   %epithelial dysplasia; MPATH:129
    %mild epithelial dysplasia ; MPATH:130
    %moderate epithelial dysplasia ; MPATH:131
    %severe epithelial dysplasia ; MPATH:132
  %hypoplasia ; MPATH:133
  %hyperplasia ; MPATH:134
   %epithelial and stromal hyperplasia ; MPATH:135
    %fibroepithelial polyp ; MPATH:136
    %fibroglandular hyperplasia ; MPATH:137
   %epithelial hyperplasia ; MPATH:138
    %goblet cell hyperplasia ; MPATH:139
    %hyperplastic polyp ; MPATH:140
    %inflammatory polyp ; MPATH:141
    %intraductal hyperplasia ; MPATH:142
    %microglandular hyperplasia ; MPATH:143
    %myoepithelial hyperplasia ; MPATH:144
   %fat cell hyperplasia ; MPATH:145
   %histiocytosis ; MPATH:146
   %lymphoid hyperplasia ; MPATH:147
   %mesothelial hyperplasia ; MPATH:148
   %squamous hyperplasia ; MPATH:149
    %acanthosis ; MPATH:150
    %actinic keratosis ; MPATH:151
    %basal cell hyperplasia ; MPATH:152
    %hypergranulosis ; MPATH:153
    %hyperkeratosis ; MPATH:154
     %orthokeratosis ; MPATH:155
     %parakeratosis ; MPATH:156
    %pseudoepithelioma/pseudocarcinoma ; MPATH:157
    %seborrheic keratosis ; MPATH:158
  %hypertrophy ; MPATH:159
  %metaplasia ; MPATH:160
   %cartilaginous metaplasia ; MPATH:161
   %epithelial metaplasia ; MPATH:162
    %apocrine metaplasia ; MPATH:163
    %gastric metaplasia ; MPATH:164
    %glandular metaplasia ; MPATH:165
    %goblet cell metaplasia ; MPATH:166
    %intestinal metaplasia ; MPATH:167
    %lipomatous metaplasia ; MPATH:168
    %nephrogenic metaplasia ; MPATH:169
    %oncocytic metaplasia ; MPATH:170
    %squamous metaplasia ; MPATH:171
    %transitional cell metaplasia ; MPATH:172
   %myeloid metaplasia ; MPATH:173
   %osseous metaplasia ; MPATH:174
 %healing and repair ; MPATH:175
  %connective tissue replacement ; MPATH:176
   %angiogenesis ; MPATH:177
   %extracellular matrix deposition ; MPATH:178
   %fibrin deposition ; MPATH:179
   %fibroblast proliferation ; MPATH:180
   %fibrosis ; MPATH:181
   %gliosis ; MPATH:182
   %granulation tissue ; MPATH:183
   %sclerosis ; MPATH:184
  %parenchymal regeneration ; MPATH:185
   %complete parenchymal regeneration ; MPATH:186
   %incomplete parenchymal regeneration ; MPATH:187
 %immunopathology ; MPATH:188
  %hypersensitivity disease ; MPATH:189
   %type I hypersensitivity ; MPATH:190
   %type II hypersensitivity ; MPATH:191
   %type III hypersensitivity ; MPATH:192
   %type IV hypersensitivity ; MPATH:193
  %immune mediated disease ; MPATH:194
   %arthritis ; MPATH:195
   %dermatitis ; MPATH:196
   %glomerulonephritis ; MPATH:197
   %immune mediated hemolytic anaemia ; MPATH:198
   %immune mediated thrombocytopenia ; MPATH:199
   %myositis ; MPATH:200
   %vasculitis ; MPATH:201
  %immunodeficiency disease ; MPATH:202
   %general immunodeficiency disease ; MPATH:203
    %chronic/recurrent inflammatory disease ; MPATH:204
    %immunodeficiency associated infection ; MPATH:205
   %primary immunodeficiency disease ; MPATH:206
    %immunodeficiency - lymphoid defect ; MPATH:207
    %immunodeficiency - myeloid/phagocytic defect ; MPATH:208
   %secondary immunodeficiency disease ; MPATH:209
    %acquired immunodeficiency ; MPATH:210
    %failed transfer of maternal immunoglobulin ; MPATH:211
 %inflammation ; MPATH:212
  %acute inflammation ; MPATH:213
  %chronic inflammation ; MPATH:214
  %granulomatous inflammation ; MPATH:215
  %necrotic inflammation ; MPATH:216
  %ulcerative inflammation ; MPATH:217
 %neoplasia ; MPATH:218
  %adnexal and skin appendage tumor ; MPATH:219
   %apocrine adenocarcinoma ; MPATH:220
   %apocrine adenoma ; MPATH:221
   %ceruminous adenocarcinoma ; MPATH:222
   %ceruminous adenoma ; MPATH:223
   %clear cell hidradenoma ; MPATH:224
   %eccrine gland adenocarcinoma ; MPATH:225
   %eccrine gland adenoma ; MPATH:226
   %eccrine papillary adenoma ; MPATH:227
   %papillary hidradenoma ; MPATH:228
   %sebaceous adenocarcinoma ; MPATH:229
   %sebaceous adenoma ; MPATH:230
   %syringoma ; MPATH:231
   %trichoepithelioma ; MPATH:232
  %basal cell tumor ; MPATH:233
   %basal cell carcinoma ; MPATH:234
  %blood vessel tumor ; MPATH:235
   %angiofibroma ; MPATH:236
   %angiokeratoma ; MPATH:237
   %hemangioblastoma ; MPATH:238
   %hemangioendothelioma ; MPATH:239
   %hemangioma ; MPATH:240
   %hemangiopericytoma ; MPATH:241
   %hemangiosarcoma ; MPATH:242
  %central nervous system tumor ; MPATH:243
   %astrocytoma ; MPATH:244
   %choroid plexus carcinoma ; MPATH:245
   %choroid plexus papilloma ; MPATH:246
   %ependymoma benign ; MPATH:247
   %ependymoma malignant ; MPATH:248
   %glioma ; MPATH:249
   %medulloblastoma ; MPATH:250
   %meningioma ; MPATH:251
   %oligodendroglioma ; MPATH:252
   %sub-ependymoma ; MPATH:253
  %complex or mixed tumor ; MPATH:254
   %adenoacanthoma ; MPATH:255
   %carcinosarcoma ; MPATH:256
   %craniopharyngioma ; MPATH:257
   %mesodermal mixed tumor ; MPATH:258
   %mucoepidermoid carcinoma ; MPATH:259
   %mullerian mixed tumor ; MPATH:260
   %nephroblastoma ; MPATH:261
   %pulmonary blastoma ; MPATH:262
   %rhabdoid sarcoma ; MPATH:263
  %fibroepithelial tumor ; MPATH:264
   %adenofibroma ; MPATH:265
   %fibroadenoma ; MPATH:266
  %glandular tumor ; MPATH:267
   %adenocarcinoma ; MPATH:268
   %adenocarcinoma in situ ; MPATH:269
   %adenoma ; MPATH:270
   %adenomatous polyposis coli ; MPATH:271
   %bronchioloalveolar adenoma ; MPATH:272
   %bronchioloalveolar carcinoma ; MPATH:273
   %clear cell adenocarcinoma ; MPATH:274
   %comedocarcinoma ; MPATH:275
   %cystadenocarcinoma ; MPATH:276
   %cystadenoma ; MPATH:277
   %follicular adenocarcinoma ; MPATH:278
   %follicular adenoma ; MPATH:279
   %harderian gland adenoma ; MPATH:280
   %harderian gland carcinoma ; MPATH:281
   %infiltrating duct carcinoma ; MPATH:282
   %intraductal carcinoma ; MPATH:283
   %intraductal papillary carcinoma ; MPATH:284
   %intraductal papilloma ; MPATH:285
   %intraductal papillomatosis ; MPATH:286
   %islet cell adenoma ; MPATH:287
   %islet cell carcinoma ; MPATH:288
   %lobular carcinoma ; MPATH:289
   %lobular carcinoma in situ ; MPATH:290
   %medullary carcinoma ; MPATH:291
   %mucinous cystadenocarcinoma ; MPATH:292
   %mucinous cystadenoma ; MPATH:293
   %myoepithelioma ; MPATH:294
   %papillary adenocarcinoma ; MPATH:295
   %papillary adenoma ; MPATH:296
   %papillary cystadenocarcinoma ; MPATH:297
   %papillary cystadenoma ; MPATH:298
   %pinealoma ; MPATH:299
   %pineoblastoma ; MPATH:300
   %pineocytoma ; MPATH:301
   %pituicytoma ; MPATH:302
   %pseudomyxoma peritonei ; MPATH:303
   %serous adenocarcinoma ; MPATH:304
   %serous cystadenoma ; MPATH:305
   %signet ring cell carcinoma ; MPATH:306
   %thyroid C-cell adenoma ; MPATH:307
   %thyroid C-cell carcinoma ; MPATH:308
  %gonadal tumor ; MPATH:309
   %germ cell tumor ; MPATH:310
    %dermoid cyst ; MPATH:311
    %dysgerminoma ; MPATH:312
    %embryonal carcinoma ; MPATH:313
    %endodermal sinus tumor ; MPATH:314
    %gonadoblastoma ; MPATH:315
    %mixed germ cell tumor ; MPATH:316
    %seminoma ; MPATH:317
     %classical seminoma ; MPATH:318
     %spermatocytic seminoma ; MPATH:319
    %struma ovarii ; MPATH:320
    %teratocarcinoma ; MPATH:321
    %teratoma ; MPATH:322
   %gonadal somatic cell tumor ; MPATH:323
    %androblastoma ; MPATH:324
    %fibrothecoma ; MPATH:325
    %granulosa cell tumor ; MPATH:326
    %gynandroblastoma ; MPATH:327
    %leydig cell tumor ; MPATH:328
    %luteal cell tumor ; MPATH:329
    %ovarian stromal tumor ; MPATH:330
    %sertoli cell adenoma ; MPATH:331
    %sertoli-leydig cell tumor ; MPATH:332
    %sex cord tumor ; MPATH:333
    %thecoma ; MPATH:334
  %hematopoietic/lymphoid malignancies/disorder ; MPATH:335
   %leukaemia ; MPATH:336
    %erythroid leukaemia ; MPATH:337
    %granulocytic leukaemia ; MPATH:338
    %lymphatic leukaemia ; MPATH:339
    %megakaryocytic leukaemia ; MPATH:340
    %myelodysplastic disorder ; MPATH:341
    %myeloid leukaemia ; MPATH:342
   %lymphoma ; MPATH:343
    %follicle center cell lymphoma ; MPATH:344
    %immunoblastic lymphoma ; MPATH:345
    %plasma cell lymphoma ; synonym:plasmacytoma ; MPATH:346
    %small lymphocytic lymphoma ; MPATH:347
    %thymic lymphoma ; MPATH:348
   %mast cell tumor ; MPATH:349
    %mastocytoma ; MPATH:350
   %thymoma ; MPATH:351
  %hepatic tumor ; MPATH:352
   %adenoma ; MPATH:353
   %cholangiocarcinoma ; MPATH:354
   %cholangiofibroma ; MPATH:355
   %hepatoblastoma ; MPATH:356
   %hepatocellular carcinoma ; MPATH:357
  %melanocytic tumor ; MPATH:358
   %melanoma ; MPATH:359
   %melanoma in situ ; MPATH:360
   %naevus ; MPATH:361
  %mesonephroma ; MPATH:362
   %mesonephric tumor ; MPATH:363
  %mesothelial tumor ; MPATH:364
   %mesothelioma ; MPATH:365
  %neuroendocrine tumor ; MPATH:366
   %carcinoid tumor ; MPATH:367
   %endocrine adenocarcinoma ; MPATH:368
   %endocrine adenoma ; MPATH:369
   %primitive neurectodermal tumor ; synonym:PNET ; MPATH:370
   %small cell carcinoma ; MPATH:371
   %tumorlet ; MPATH:372
  %neuroepitheliomatous tumor ; MPATH:373
   %esthesioneuroblastoma ; MPATH:374
   %ganglioneuroma ; MPATH:375
   %neuroblastoma ; MPATH:376
   %phaeochromocytoma ; MPATH:377
   %retinoblastoma ; MPATH:378
  %odontogenic tumor ; MPATH:379
   %ameloblastic fibroma ; MPATH:380
   %ameloblastoma ; MPATH:381
   %cementifying fibroma ; MPATH:382
   %cementoblastoma ; MPATH:383
   %cementoma ; MPATH:384
   %dentinoma ; MPATH:385
   %odontogenic tumor ; MPATH:386
   %odontoma ; MPATH:387
  %osseous and chondromatous tumor ; MPATH:388
   %chondroblastoma ; MPATH:389
   %chondroblastoma, malignant ; MPATH:390
   %chondromatosis ; MPATH:391
   %chondrosarcoma ; MPATH:392
   %osteoblastoma ; MPATH:393
   %osteochondroma ; MPATH:394
   %osteofibroma ; MPATH:395
   %osteoma ; MPATH:396
   %osteosarcoma ; MPATH:397
  %paragangliomas and glomus tumor ; MPATH:398
   %aortic body tumor ; MPATH:399
   %carotid body tumor ; MPATH:400
   %glomus jugulare tumor ; MPATH:401
   %glomus tumor ; MPATH:402
   %paraganglioma ; MPATH:403
  %soft tissue tumor ; MPATH:404
   %chordoma ; MPATH:405
   %dermatofibrosarcoma ; MPATH:406
   %soft tissue fibroma ; MPATH:407
   %soft tissue fibrosarcoma ; MPATH:408
   %fibrous histiocytoma ; MPATH:409
   %giant cell tumor of soft tissue ; MPATH:410
   %granular cell tumor/alveolar sarcoma ; MPATH:411
    %alveolar soft part sarcoma ; MPATH:412
    %granular cell tumor ; MPATH:413
   %histiocytic sarcoma ; MPATH:414
   %lipomatous tumor ; MPATH:415
    %angiomyolipoma ; MPATH:416
    %lipoma ; MPATH:417
     %liposarcoma ; MPATH:418
   %lymphatic vessel tumor ; MPATH:419
    %lymphangioma ; MPATH:420
    %lymphangiomyomatosis ; MPATH:421
    %lymphangiosarcoma ; MPATH:422
   %myomatous tumor ; MPATH:423
    %intravascular leiomyomatosis ; MPATH:424
    %leiomyoma ; MPATH:425
    %leiomyosarcoma ; MPATH:426
    %myoblastoma ; MPATH:427
    %rhabdomyosarcoma ; MPATH:428
   %myxomatous tumor ; MPATH:429
    %angiomyxoma ; MPATH:430
    %myxoma ; MPATH:431
    %myxosarcoma ; MPATH:432
   %nerve sheath tumor ; MPATH:433
    %neurilemmoma ; MPATH:434
    %neurofibroma ; MPATH:435
    %neurofibromatosis ; MPATH:436
    %neurofibrosarcoma ; MPATH:437
    %schwannoma ; MPATH:438
   %synovial-like tumor ; MPATH:439
    %synovial sarcoma ; MPATH:440
    %synovioma ; MPATH:441
  %squamous cell tumor ; MPATH:442
   %inverted papilloma ; MPATH:443
   %keratoacanthoma ; MPATH:444
   %papilloma ; MPATH:445
   %squamous cell carcinoma ; MPATH:446
   %squamous cell carcinoma in situ ; MPATH:447
   %squamous cell papilloma ; MPATH:448
   %verrucous carcinoma ; MPATH:449
  %transitional cell tumor ; MPATH:450
   %transitional cell carcinoma ; MPATH:451
   %transitional cell carcinoma in situ ; MPATH:452
   %transitional cell papilloma ; MPATH:453
  %trophoblastic tumor ; MPATH:454
   %choriocarcinoma ; MPATH:455
   %hydatidiform mole ; MPATH:456
   %placental site trophoblastic tumor ; MPATH:457
 %normal ; MPATH:458